Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644136 · ClinicalTrials.gov registry record · NA
Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT01644136: Clinical Trial NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01644136 is a NA study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01644136, a NA study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections can become symptomatic in some patients. Arista would be applied to one side of the pelvis after a pelvic lymph node dissection, to see if this decreases the number of postoperative lymph fluid collections seen on a computed tomography (CT) scan after surgery
Primary Outcome
The rate of lymphoceles on each side of the pelvis will be compared. Summary statistics will be reported (mean, standard deviation, and range for the continuous variables and frequency and percentages for the categorical variables). In addition, we will determine interrelationships among specific variables using regression and correlation analyses.
Interventions
- PROCEDURE robot-assisted laparoscopic surgery
- PROCEDURE regional lymph node dissection
- DEVICE microsphere-mediated lymphocele prevention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-07-14 |
| Est. Completion | 2014-05-06 |
| Phase | NA |
Why NCT01644136 stopped before completion
NCT01644136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which robot-assisted laparoscopic surgery is the first listed.
NCT01644136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01644136 about?
NCT01644136 is a clinical study titled "Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer". This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections...
What is the current status of trial NCT01644136?
This trial is currently terminated. It is a NA study. The enrollment target is 99 participants. The study started on 2011-07-14. Estimated completion is 2014-05-06.
What interventions are being tested in trial NCT01644136?
The interventions under investigation include: robot-assisted laparoscopic surgery (PROCEDURE), regional lymph node dissection (PROCEDURE), microsphere-mediated lymphocele prevention (DEVICE).
Who is sponsoring clinical trial NCT01644136?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01644136's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI